Breast Cancer

May 09, 2025

ENHERTU, a next-generation antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo/ AstraZeneca since March 2019, except in Japan, where Daiichi Sankyo maintains exclusive rights. It is worth noting that recently, in November 2024, Daiichi Sankyo and AstraZeneca were awarded the Galien Foundation 2024 Pri...

Mar 27, 2025

Alcon Announced CE Mark Approval and Launch of Clareon Vivity IOL in Europe, Expanding Visual Options  On March 25, 2025, Alcon, the global leader in eye care committed to enhancing vision, announced that Vivity®, the most widely implanted extended depth of focus (EDOF) intraocular lens (IOL), became availa...

Dec 09, 2024

In the rapidly evolving landscape of cancer therapy, one class of drugs is making waves for its game-changing impact: CDK4/6 inhibitors. These revolutionary agents are rewriting the narrative for treating cancers driven by uncontrolled cell division, particularly hormone receptor-positive, HER2-negative breast canc...

Nov 04, 2024

Cyclin-dependent kinase 7 (CDK7) belongs to the CDK family of serine/threonine protein kinases and plays a crucial role in regulating the cell cycle and mRNA transcription. It is often overexpressed in various cancers, making it a promising target for cancer treatment due to its involvement in both transcription an...

Aug 14, 2024

Breast cancer is the most common form of cancer in women. Each year, it affects over 2 million women globally and is the most significant cause of death among women. Among the many types of breast cancer, a particularly formidable foe is Triple-negative breast cancer (TNBC), which accounts for 10-20% of all cases. ...

Aug 13, 2024

For most of the last century, breast cancer was categorized only by its location in the body; as a result, treatment results varied significantly. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. In September 1998, th...

Aug 13, 2024

Every year during Breast Cancer Awareness Month, numerous campaigns aim to raise awareness about breast cancer, its symptoms, early diagnosis, and treatment options. Significant progress has been made in managing breast cancer, assessing its risks, and treating it through a combination of surgery, radiation, and ot...

Aug 08, 2024

Breast cancer is a serious and most common problem in developed as well as developing countries. According to the World Health Organization (WHO), more than 2.3 million cases of breast cancer occur each year, making it the most common cancer among adults. In 95% of countries, breast cancer is either the leading ...

Aug 08, 2024

HR+/HER2- Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast cancers. Hormone receptors are proteins that receive hormone signals and cue the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumo...

Aug 08, 2024

More than a dozen companies have shifted their focus toward the development of HR-positive/HER2-negative breast cancer drugs. Some of them are Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Seagen Inc.,...